A potential association between IL‐3 and type I and III interferons in systemic lupus erythematosus

A potential association between IL‐3 and type I and III interferons in systemic lupus erythematosus

Abstract Objectives Plasmacytoid dendritic cells (pDCs), through the production of type 1 interferons (IFNs) and other cytokines, are major contributors to systemic lupus erythematosus (SLE) pathogenesis. IL‐3 promotes pDC survival, but its role in SLE is not well characterised. This study investiga...

Full description

Bibliographic Details
Main Authors:	Shereen Oon, Katherine Monaghan, Milica Ng, Alberta Hoi, Eric Morand, Gino Vairo, Eugene Maraskovsky, Andrew D Nash, Ian P Wicks, Nicholas J Wilson
Format:	Article
Language:	English
Published:	Wiley 2019-01-01
Series:	Clinical & Translational Immunology
Subjects:	cytokines gene signature immunological disorders interferons interleukin-3 systemic lupus erythematosus
Online Access:	https://doi.org/10.1002/cti2.1097

Similar Items

Interferon alpha (IFN-α) in systemic lupus erythematosus (SLE)
by: Sara Moqbil, et al.
Published: (2022-11-01)

Interferon score is increased in incomplete systemic lupus erythematosus and correlates with myxovirus-resistance protein A in blood and skin
by: Wietske M. Lambers, et al.
Published: (2019-12-01)

The Pathogenesis, Molecular Mechanisms, and Therapeutic Potential of the Interferon Pathway in Systemic Lupus Erythematosus and Other Autoimmune Diseases
by: Madhu Ramaswamy, et al.
Published: (2021-10-01)

Cytokines and autoantibodies profile during systemic lupus erythematosus and psoriasis diseases in Egypt
by: Alyaa Farid, et al.
Published: (2022-06-01)

IRF4 and IRGs Delineate Clinically Relevant Gene Expression Signatures in Systemic Lupus Erythematosus and Rheumatoid Arthritis
by: Javier Rodríguez-Carrio, et al.
Published: (2019-01-01)

Comparative characteristics of immunological tests in differentiation of systemic and integument forms of lupus erythematosus
by: N V Romanova, et al.
Published: (2009-04-01)

Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus
by: I-Tsu Chyuan, et al.
Published: (2019-08-01)

Type I Interferons in Systemic Lupus Erythematosus: A Journey from Bench to Bedside
by: Tao Ming Sim, et al.
Published: (2022-02-01)

IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE)
by: Vilija Oke, et al.
Published: (2017-06-01)

Interferon-λ3/4 genetic variants and interferon-λ3 serum levels are biomarkers of lupus nephritis and disease activity in Taiwanese
by: Ji-Yih Chen, et al.
Published: (2018-08-01)

Measurement of serum interferon alpha in Egyptian patients with systemic lupus erythematosus and evaluation of its effect on disease activity: a case-control study
by: A. Fayed, et al.
Published: (2020-11-01)

Cytokines as Biomarkers in Systemic Lupus Erythematosus: Value for Diagnosis and Drug Therapy
by: Helena Idborg, et al.
Published: (2021-10-01)

Rapid Response of Refractory Systemic Lupus Erythematosus Skin Manifestations to Anifrolumab—A Case-Based Review of Clinical Trial Data Suggesting a Domain-Based Therapeutic Approach
by: Marlene Plüß, et al.
Published: (2022-06-01)

Is Th17-Targeted Therapy Effective in Systemic Lupus Erythematosus?
by: Marin Petrić, et al.
Published: (2023-05-01)

The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus
by: Lloyd Mai, et al.
Published: (2021-01-01)

Interferon in systemic lupus erythematosus—A halfway between monogenic autoinflammatory and autoimmune disease
by: Ioana Saulescu, et al.
Published: (2022-11-01)

Type I interferon pathway activation across the antiphospholipid syndrome spectrum: associations with disease subsets and systemic antiphospholipid syndrome presentation
by: Irene Cecchi, et al.
Published: (2024-03-01)

Proteome study of cutaneous lupus erythematosus (CLE) and dermatomyositis skin lesions reveals IL-16 is differentially upregulated in CLE
by: Timothy B. Niewold, et al.
Published: (2021-04-01)

Lupus Enteritis: An Uncommon Manifestation of Systemic Lupus Erythematosus as an Initial Presentation
by: Vishal Bodh, et al.
Published: (2017-07-01)

IMMUNOINFLAMMATORY RHEUMATIC DISEASES ASSOCIATED WITH TYPE I INTERFERON: NEW EVIDENCE
by: E. L. Nasonov, et al.
Published: (2019-09-01)

Correlation of plasma interleukin-18 concentration and severity of renal involvement and disease activity in systemic lupus erythematosus
by: Mohammad Reza Jafari-Nakhjavani, et al.
Published: (2016-01-01)

Vitamin D supplementation in systemic lupus erythematosus: relationship to disease activity, fatigue and the interferon signature gene expression
by: Rosalie Magro, et al.
Published: (2021-12-01)

Identification of key interferon-stimulated genes for indicating the condition of patients with systemic lupus erythematosus
by: Mengjia Shen, et al.
Published: (2022-07-01)

2-Arachidonoylglycerol Reduces the Production of Interferon-Gamma in T Lymphocytes from Patients with Systemic Lupus Erythematosus
by: Luca Navarini, et al.
Published: (2022-07-01)

Clinical and serological manifestations associated with interferon-α levels in childhood-onset systemic lupus erythematosus
by: Mariana Postal, et al.
Published: (2012-01-01)

Serum interleukin-18 and its relationship with subclinical atherosclerosis in systemic lupus erythematosus
by: Zahra Rezaieyazdi, et al.
Published: (2022-01-01)

Interleukin-18 in systemic lupus erythematosus: link with clinical symptoms and vascular atherosclerosis
by: T A Panafidina, et al.
Published: (2008-05-01)

Clinical Relevance of Autoantibodies against Interleukin-2 in Patients with Systemic Lupus Erythematosus
by: Miao Shao, et al.
Published: (2018-01-01)

Serum interleukin-18 and interleukin-10 levels in systemic lupus erythematosus: correlation with SLEDAI score and disease activity parameters
by: Sahar Abou El-Fetouh, et al.
Published: (2014-01-01)

New possibilities of pharmacotherapy for systemic lupus erythematosus: Prospects for the use of anifrolumab (monoclonal antibodies to type I interferon receptor)
by: E. L. Nasonov, et al.
Published: (2021-10-01)

Correlation between Interleukin-4 and Interleukin-6 and auto antibodies in Systemic Lupus Erythematosus.
by: Sajid N. Abdualkader, et al.
Published: (2010-01-01)

The association between serum prolactin levels and interleukin-6 and systemic lupus erythematosus activity
by: W.A. Wan Asyraf, et al.
Published: (2018-12-01)

Clinical and serological manifestations associated with interferon-α levels in childhood-onset systemic lupus erythematosus
by: Mariana Postal, et al.
Published: (2012-01-01)

Nucleic Acid Sensors and Type I Interferon Production in Systemic Lupus Erythematosus
by: Meena eShrivastav, et al.
Published: (2013-10-01)

Lack of Association between Serum Interleukin-23 and Interleukin-27 Levels and Disease Activity in Patients with Active Systemic Lupus Erythematosus
by: Katarzyna Pawlak-Buś, et al.
Published: (2021-10-01)

Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date
by: Felten R, et al.
Published: (2019-05-01)

Interleukin-6 and disease activity in childhood systemic lupus erythematosus
by: Cahya Dewi Satria, et al.
Published: (2023-11-01)

Current concepts of photosensitivity in cutaneous lupus erythematosus
by: Benjamin Klein, et al.
Published: (2022-08-01)

Low-density granulocytes are related to shorter pregnancy duration but not to interferon alpha protein blood levels in systemic lupus erythematosus
by: Agnes Torell, et al.
Published: (2023-06-01)

A teen with blaschkolinear tumid lupus erythematosus
by: Amy Shen, BS, et al.
Published: (2022-03-01)